Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bristol-Myers Squibb Co's Debt-to-EBITDA or its related term are showing as below:
XSWX:BMY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.04 Med: 2.2 Max: 16.16
Current: 3.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of Bristol-Myers Squibb Co was 16.16. The lowest was 1.04. And the median was 2.20.
XSWX:BMY's Debt-to-EBITDA is ranked worse than 69.38% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs XSWX:BMY: 3.10
Bristol-Myers Squibb Co (XSWX:BMY) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bristol-Myers Squibb Co Debt-to-EBITDA Related Terms
Bristol-Myers Squibb Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BMY vs PFE, GILD, AMGN: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Bristol-Myers Squibb Co (XSWX:BMY) has a Debt-to-EBITDA of 2.73 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bristol-Myers Squibb Co. This is 24% above median its historical median of 2.20. Over the past decade, Bristol-Myers Squibb Co's Debt-to-EBITDA has ranged from 1.04 to 16.16. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #478 out of 689 companies in the Drug Manufacturers industry, placing it in the top 69.4%.
Is Bristol-Myers Squibb Co's Debt-to-EBITDA too high?
Bristol-Myers Squibb Co's current Debt-to-EBITDA of 2.73 is 24% above median its 10-year median of 2.20. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 16.16. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Bristol-Myers Squibb Co's value of 2.73 is 62.5% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #478 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Debt-to-EBITDA compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #478 out of 689 companies for Debt-to-EBITDA. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Bristol-Myers Squibb Co's value of 2.73 is 62.5% above this benchmark. Historically, Bristol-Myers Squibb Co's own Debt-to-EBITDA has ranged from 1.04 to 16.16 over the past decade. While the company's 10-year median is 2.20 vs. the industry median of 1.68, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Debt-to-EBITDA of 2.73 is 62.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bristol-Myers Squibb Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Debt-to-EBITDA is 2.73, which is 24% above median its own 10-year median of 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Debt-to-EBITDA of 2.73. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current Debt-to-EBITDA is 2.73, which is 24% above median its 10-year median of 2.20 and 62.5% above the Drug Manufacturers industry median of 1.68. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Debt-to-EBITDA is 2.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.
Key valuation signals for XSWX:BMY:
Debt-to-EBITDA: 2.73 (24% above median its 10-year median of 2.20)
GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
Industry Position: 62.5% above the Drug Manufacturers median (#478 of 689)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score
Get the complete analysis for XSWX:BMY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
